| Title |
Amyloid Imaging: Poised for Integration into Medical Practice
|
|---|---|
| Published in |
Neurotherapeutics, January 2017
|
| DOI | 10.1007/s13311-016-0474-y |
| Pubmed ID | |
| Authors |
Keshav Anand, Marwan Sabbagh |
| Abstract |
Amyloid imaging represents a significant advance as an adjunct in the diagnosis of Alzheimer's disease (AD) because it is the first imaging modality that identifies in vivo changes known to be associated with the pathogenesis. Initially, (11)C-PIB was developed, which was the prototype for many (18)F compounds, including florbetapir, florbetaben, and flutemetamol, among others. Despite the high sensitivity and specificity of amyloid imaging, it is not commonly used in clinical practice, mainly because it is not reimbursed under current Center for Medicare and Medicaid Services guidelines in the USA. To guide the field in who would be most appropriate for the utility of amyloid positron emission tomography, current studies are underway [Imaging Dementia Evidence for Amyloid Scanning (IDEAS) Study] that will inform the field on the utilization of amyloid positron emission tomography in clinical practice. With the advent of monoclonal antibodies that specifically target amyloid antibody, there is an interest, possibly a mandate, to screen potential treatment recipients to ensure that they are suitable for treatment. In this review, we summarize progress in the field to date. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 88 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Greece | 1 | 1% |
| Unknown | 87 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 15% |
| Student > Bachelor | 12 | 14% |
| Student > Ph. D. Student | 11 | 13% |
| Other | 7 | 8% |
| Student > Doctoral Student | 6 | 7% |
| Other | 12 | 14% |
| Unknown | 27 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 26% |
| Neuroscience | 10 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
| Agricultural and Biological Sciences | 3 | 3% |
| Chemistry | 3 | 3% |
| Other | 15 | 17% |
| Unknown | 29 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 August 2021.
All research outputs
#2,759,541
of 25,371,288 outputs
Outputs from Neurotherapeutics
#263
of 1,308 outputs
Outputs of similar age
#53,337
of 421,641 outputs
Outputs of similar age from Neurotherapeutics
#10
of 23 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,308 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.2. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 421,641 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.